Bayer's Asundexian Starts EU Review for Ischaemic Stroke

Why It Matters

If approved, asundexian would become the first Factor XIa blocker for stroke prevention, offering a safer alternative to existing therapies and bolstering Bayer’s earnings amid shrinking Xarelto sales.

Key Takeaways

• Asundexian cuts secondary stroke risk by 26% in OCEANIC‑STROKE.
• EMA review positions Bayer ahead of milvexian's pending results.
• No increase in major bleeding observed with asundexian addition.
• Stroke impacts 10 million Europeans; 20% face another event.
• Asundexian may offset Xarelto revenue loss of $2.6 bn.

Pulse Analysis

Stroke remains a leading cause of death and disability in Europe, affecting roughly 10 million people and generating close to $891 billion in global healthcare costs each year. Current secondary‑prevention options, such as aspirin or clopidogrel, leave about one‑in‑five patients vulnerable to a repeat event, underscoring the urgent need for therapies that can break this cycle without adding bleeding risk.

Asundexian, an oral Factor XIa inhibitor, targets the intrinsic coagulation pathway, offering antithrombotic efficacy while sparing platelet function. In the pivotal OCEANIC‑STROKE trial, adding asundexian to standard antiplatelet therapy cut recurrent ischemic strokes by 26% and lowered the composite of cardiovascular death, myocardial infarction or stroke, all without a rise in major bleeding. The EMA’s acceptance of Bayer’s marketing‑authorisation application places the company ahead of Bristol Myers Squibb‑Johnson & Johnson’s milvexian, whose LIBREXIA‑STROKE data are expected later this year.

For Bayer, a positive opinion could partially offset the revenue erosion from Xarelto, whose patent expiry reduced sales to $2.6 billion in 2025. A successful launch would diversify Bayer’s anticoagulation portfolio, open a multibillion‑dollar market segment, and reinforce its reputation for innovative hematology solutions. Investors and clinicians alike will watch the EMA’s final decision closely, as it may reshape the competitive landscape for next‑generation antithrombotic drugs.